Caris Life Sciences, Inc. (CAI)
NASDAQ: CAI · Real-Time Price · USD
18.47
-0.07 (-0.38%)
At close: Mar 18, 2026, 4:00 PM EDT
18.00
-0.47 (-2.54%)
After-hours: Mar 18, 2026, 5:27 PM EDT
Caris Life Sciences Stock Forecast
Stock Price Forecast
The 9 analysts that cover Caris Life Sciences stock have a consensus rating of "Strong Buy" and an average price target of $32.78, which forecasts a 77.48% increase in the stock price over the next year. The lowest target is $22 and the highest is $42.
Price Target: $32.78 (+77.48%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Caris Life Sciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 4 | 4 |
| Buy | 3 | 3 | 3 | 3 | 4 | 4 |
| Hold | 0 | 0 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 7 | 7 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Hold Maintains $30 → $22 | Hold | Maintains | $30 → $22 | +19.11% | Mar 13, 2026 |
| Evercore ISI Group | Evercore ISI Group | Buy Maintains $38 → $34 | Buy | Maintains | $38 → $34 | +84.08% | Feb 27, 2026 |
| Baird | Baird | Buy Maintains $26 → $28 | Buy | Maintains | $26 → $28 | +51.60% | Feb 27, 2026 |
| BTIG | BTIG | Strong Buy Maintains $45 → $38 | Strong Buy | Maintains | $45 → $38 | +105.74% | Feb 27, 2026 |
| Baird | Baird | Buy Initiates $26 | Buy | Initiates | $26 | +40.77% | Feb 17, 2026 |
Financial Forecast
Revenue This Year
1.01B
from 812.03M
Increased by 24.26%
Revenue Next Year
1.24B
from 1.01B
Increased by 22.60%
EPS This Year
0.19
from -3.22
EPS Next Year
0.39
from 0.19
Increased by 100.91%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 1.1B | 1.4B | |||
| Avg | 1.0B | 1.2B | |||
| Low | 945.7M | 1.2B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 30.9% | 34.3% | |||
| Avg | 24.3% | 22.6% | |||
| Low | 16.5% | 14.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 0.48 | 0.56 | |||
| Avg | 0.19 | 0.39 | |||
| Low | 0.05 | 0.14 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | 188.8% | |||
| Avg | - | 100.9% | |||
| Low | - | -28.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.